Cargando…
An Updated Systematic Review With Meta-Analysis Of Randomized Trials On Topical Cyclosporin A For Dry-Eye Disease
BACKGROUND/AIMS: To evaluate the effects of topical cyclosporin A (CsA) and artificial tears (ATs) for treating patients with dry-eye disease (DED). METHODS: On January 25, 2019, five electronic databases and reference lists were searched for randomized clinical trials (RCTs) comparing CsA with ATs...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6974131/ https://www.ncbi.nlm.nih.gov/pubmed/32021110 http://dx.doi.org/10.2147/DDDT.S207743 |
_version_ | 1783490064294084608 |
---|---|
author | Tuan, Hsin-I Chi, Sheng-Chu Kang, Yi-No |
author_facet | Tuan, Hsin-I Chi, Sheng-Chu Kang, Yi-No |
author_sort | Tuan, Hsin-I |
collection | PubMed |
description | BACKGROUND/AIMS: To evaluate the effects of topical cyclosporin A (CsA) and artificial tears (ATs) for treating patients with dry-eye disease (DED). METHODS: On January 25, 2019, five electronic databases and reference lists were searched for randomized clinical trials (RCTs) comparing CsA with ATs among patients with DED. The search strategy had no restriction on language or time. Two authors extracted surgery, mean age, anesthesia for Schirmer’s test, tear-breakup time, Schirmer’s test score, fluorescein-staining score, ocular surface–disease index, and adverse events. Mean differences (MDs) were calculated for continuous outcomes and Peto ORs for dichotomous data with zero cells. Results were analyzed with 95% CIs in a random-effect model. RESULTS: Eleven RCTs recruiting 1,085 cases with DED were included. Pooled results showed that CsA had better tear-breakup time (MD 0.94, 95% CI 0.08–1.80), fluorescein-staining score (standardized MD −0.72, 95% CI −1.28 to −0.16), and ocular surface–disease index (MD −4.75, 95% CI −6.31 to −3.18) when compared to ATs. Although CsA had more adverse events than ATs (Peto OR 7.70, 95% CI 3.17–18.68), no serious adverse events were reported. CONCLUSION: Overall, CsA is an effective option for treating patients with DED, yet our evidence indicated decreasing effects when CsA was combined with ATs. CsA may be worth suggesting to relatively older patients with DED. We anticipate further RCTs to explore the effects of treatment duration, optimal dosage, and efficacy of CsA in different DED etiology. |
format | Online Article Text |
id | pubmed-6974131 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-69741312020-02-04 An Updated Systematic Review With Meta-Analysis Of Randomized Trials On Topical Cyclosporin A For Dry-Eye Disease Tuan, Hsin-I Chi, Sheng-Chu Kang, Yi-No Drug Des Devel Ther Original Research BACKGROUND/AIMS: To evaluate the effects of topical cyclosporin A (CsA) and artificial tears (ATs) for treating patients with dry-eye disease (DED). METHODS: On January 25, 2019, five electronic databases and reference lists were searched for randomized clinical trials (RCTs) comparing CsA with ATs among patients with DED. The search strategy had no restriction on language or time. Two authors extracted surgery, mean age, anesthesia for Schirmer’s test, tear-breakup time, Schirmer’s test score, fluorescein-staining score, ocular surface–disease index, and adverse events. Mean differences (MDs) were calculated for continuous outcomes and Peto ORs for dichotomous data with zero cells. Results were analyzed with 95% CIs in a random-effect model. RESULTS: Eleven RCTs recruiting 1,085 cases with DED were included. Pooled results showed that CsA had better tear-breakup time (MD 0.94, 95% CI 0.08–1.80), fluorescein-staining score (standardized MD −0.72, 95% CI −1.28 to −0.16), and ocular surface–disease index (MD −4.75, 95% CI −6.31 to −3.18) when compared to ATs. Although CsA had more adverse events than ATs (Peto OR 7.70, 95% CI 3.17–18.68), no serious adverse events were reported. CONCLUSION: Overall, CsA is an effective option for treating patients with DED, yet our evidence indicated decreasing effects when CsA was combined with ATs. CsA may be worth suggesting to relatively older patients with DED. We anticipate further RCTs to explore the effects of treatment duration, optimal dosage, and efficacy of CsA in different DED etiology. Dove 2020-01-17 /pmc/articles/PMC6974131/ /pubmed/32021110 http://dx.doi.org/10.2147/DDDT.S207743 Text en © 2020 Tuan et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Tuan, Hsin-I Chi, Sheng-Chu Kang, Yi-No An Updated Systematic Review With Meta-Analysis Of Randomized Trials On Topical Cyclosporin A For Dry-Eye Disease |
title | An Updated Systematic Review With Meta-Analysis Of Randomized Trials On Topical Cyclosporin A For Dry-Eye Disease |
title_full | An Updated Systematic Review With Meta-Analysis Of Randomized Trials On Topical Cyclosporin A For Dry-Eye Disease |
title_fullStr | An Updated Systematic Review With Meta-Analysis Of Randomized Trials On Topical Cyclosporin A For Dry-Eye Disease |
title_full_unstemmed | An Updated Systematic Review With Meta-Analysis Of Randomized Trials On Topical Cyclosporin A For Dry-Eye Disease |
title_short | An Updated Systematic Review With Meta-Analysis Of Randomized Trials On Topical Cyclosporin A For Dry-Eye Disease |
title_sort | updated systematic review with meta-analysis of randomized trials on topical cyclosporin a for dry-eye disease |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6974131/ https://www.ncbi.nlm.nih.gov/pubmed/32021110 http://dx.doi.org/10.2147/DDDT.S207743 |
work_keys_str_mv | AT tuanhsini anupdatedsystematicreviewwithmetaanalysisofrandomizedtrialsontopicalcyclosporinafordryeyedisease AT chishengchu anupdatedsystematicreviewwithmetaanalysisofrandomizedtrialsontopicalcyclosporinafordryeyedisease AT kangyino anupdatedsystematicreviewwithmetaanalysisofrandomizedtrialsontopicalcyclosporinafordryeyedisease AT tuanhsini updatedsystematicreviewwithmetaanalysisofrandomizedtrialsontopicalcyclosporinafordryeyedisease AT chishengchu updatedsystematicreviewwithmetaanalysisofrandomizedtrialsontopicalcyclosporinafordryeyedisease AT kangyino updatedsystematicreviewwithmetaanalysisofrandomizedtrialsontopicalcyclosporinafordryeyedisease |